Mylan Stock Buy Or Sell May 2026

Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .

Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion . mylan stock buy or sell

Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds. Discounted Cash Flow (DCF) models suggest the stock

The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. Its low valuation and steady dividends may make

Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook

Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors.

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).